Cambrex announces $425m acquisition of American CDMO Halo Pharma
Cambrex Corporation, a leading manufacturer of small molecules and generic Active Pharmaceutical Ingredients (APIs), has announced a strategic acquisition of Halo Pharma for $425 million. ... Read More
Cambrex set to acquire Halo Pharma for $425m to expand into finished dosage form market
In a significant expansion of its capabilities, Cambrex Corporation has announced its agreement to acquire Halo Pharma, a US-based contract development and manufacturing organization (CDMO), ... Read More